Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Systemic treatment following immunotherapy

Alastair Greystoke • 30 Jan 2020
BTOG 2020
Lung Cancer

Alastair Greystoke, MBChB, MSc, PhD, MRCP, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK, outlines a paper he recently co-authored regarding systemic treatment following immunotherapy. The study aimed to assess whether patients were remaining on immunotherapy for too long, and hence not healthy enough to progress onto further treatment regimens. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Alastair Greystoke

6:20
Solid tumor genomic testing in the UK: challenges and solutions
Alastair Greystoke • 28 Apr 2023
1:51
NHS England: a pilot ctDNA study to track patient responses to novel genomic targets
Alastair Greystoke • 27 Apr 2023
5:59
Deciphering an NGS report in lung cancer
Alastair Greystoke • 24 Jan 2022
3:34
Strategies to improve biomarker testing in the UK
Alastair Greystoke • 24 Jan 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals